Related Experiment Video
Updated: Dec 6, 2025

Measuring RAN Peptide Toxicity in C. elegans
Published on: April 30, 2020
Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity
Alan S Premasiri1, Anna L Gill1, Fernando G Vieira1
1ALS Therapy Development Institute, Cambridge, MA, United States.
Abstract:
Repeat expansion mutations in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Repeat-associated non-AUG translation of this expansion produces dipeptide repeat proteins (DRPs). The arginine containing DRPs, polyGR and polyPR, are consistently reported to be the most toxic. Here we demonstrated that small molecule inhibition of type I protein arginine methyltransferases (PRMT) protects against polyGR and polyPR toxicity. Furthermore, our findings suggest that asymmetric dimethylation of polyGR and polyPR by Type I PRMTs plays important roles in their cytotoxicity.
Insights
Small molecules targeting protein arginine methyltransferases (PRMTs) reduce toxicity from C9ORF72 repeat expansions, a key cause of ALS and FTD. This suggests PRMT inhibition is a potential therapeutic strategy for these neurodegenerative diseases.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- C9ORF72 repeat expansions are the leading genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
- These expansions produce toxic dipeptide repeat proteins (DRPs), with arginine-containing polyGR and polyPR being particularly harmful.
Purpose of the Study:
- To investigate the role of protein arginine methyltransferases (PRMTs) in the toxicity of polyGR and polyPR.
- To evaluate the therapeutic potential of inhibiting Type I PRMTs against C9ORF72-associated neurotoxicity.
Main Methods:
- Utilized cell models expressing polyGR and polyPR to assess toxicity.
- Administered small molecule inhibitors targeting Type I PRMTs.
- Analyzed the impact of PRMT inhibition on DRP cytotoxicity and methylation status.
Main Results:
- Small molecule inhibition of Type I PRMTs significantly protected against polyGR and polyPR toxicity.
- Evidence suggests that asymmetric dimethylation of polyGR and polyPR by Type I PRMTs is crucial for their cytotoxic effects.
Conclusions:
- Type I PRMTs and their methylation activity are key contributors to the toxicity of C9ORF72-associated DRPs.
- Inhibiting Type I PRMTs represents a promising therapeutic avenue for treating ALS and FTD caused by C9ORF72 repeat expansions.
Related Concept Videos
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Regulation of the Unfolded Protein Response
Abnormal Proliferation
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
The Unfolded Protein Response

